March 3, 2020 / 12:53 PM / a month ago

BRIEF-Nature Gene Therapy Publishes Preclinical Data Of Ocugen’S OCU400 Genetic Modifier To Treat Retinitis Pigmentosa

March 3 (Reuters) - Ocugen Inc:

* NATURE GENE THERAPY PUBLISHES PRECLINICAL DATA OF OCUGEN’S OCU400 (NR2E3-AAV) GENETIC MODIFIER TO TREAT RETINITIS PIGMENTOSA (RP)

* OCUGEN INC - PUBLICATION DETAILS EFFICACY RESULTS IN FIVE UNIQUE MOUSE MODELS OF RETINITIS PIGMENTOSA THAT UNDERWENT ADMINISTRATION OF NR2E3-AAV Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below